Masteron vs Nandrolone
Moderate Research vs FDA Approved
avoid Mechanism-based · 60% Both Masteron and Nandrolone carry cardiovascular risk. Combined cardiotoxic load increases risk of cardiac events. Regular cardiac monitoring recommended.
Molecular Data
Masteron Nandrolone
Weight 304.47 Da (base) 274.40 Da (base)
Half-life ~2 days (propionate), ~10 days (enanthate) ~6-12 days (decanoate)
Type DHT-derived anabolic steroid (C20H32O2) 19-nortestosterone steroid (C18H26O2)
Key Benefits
Masteron
01 Produces a hard, dry, and grainy appearance by eliminating subcutaneous water retention
02 Mild anti-estrogenic properties that can reduce or replace the need for aromatase inhibitors on cycle
03 Does not aromatize, eliminating estrogen-mediated side effects from the compound itself
04 Enhances the visual effects of other steroids in a stack by reducing water retention and bloat
05 Modest increases in strength without significant weight gain, useful for weight-class athletes
06 Improves muscle density and vascularity at low body fat percentages
07 Well-tolerated with a relatively mild side effect profile compared to other anabolic steroids
08 Short detection window with propionate ester compared to many other injectable steroids
Nandrolone
01 Significant increases in lean muscle mass with a favorable anabolic-to-androgenic ratio
02 Enhanced collagen synthesis and joint lubrication, reducing joint pain and improving connective tissue integrity
03 Increased bone mineral density through direct osteoblast stimulation
04 Improved nitrogen retention and protein synthesis for accelerated recovery
05 Stimulation of erythropoietin production, increasing red blood cell mass and oxygen delivery
06 Lower androgenic side effects (hair loss, acne, prostate enlargement) compared to testosterone
07 Clinically demonstrated efficacy in treating anemia of chronic renal failure
08 Potential neuroprotective properties observed in preclinical research
Dosing Protocols
Masteron
300-500 mg/week / Every other day (propionate) or 2x per week (enanthate)
Cutting / Aesthetic Enhancement 300-400 mg/week Every other day (propionate) or 2x per week (enanthate)
Contest Preparation 400-500 mg/week Every other day or daily (propionate)
AI Replacement / Estrogen Management 200-300 mg/week Every other day (propionate) or 2x per week (enanthate)
Nandrolone
100-200 mg/week (therapeutic) / 1x per week (decanoate) or 2-3x per week (NPP)
TRT Adjunct - Joint Support 50-100 mg/week 1x per week (decanoate)
Therapeutic - Anemia / Wasting 100-200 mg/week 1x per week (decanoate)
Performance Enhancement - Moderate 200-400 mg/week 1x per week (decanoate) or split into 2 injections
NPP Protocol - Shorter Cycle 200-350 mg/week Every other day or 3x per week
Side Effects
Masteron
Hair loss and accelerated male pattern baldness (significant risk as a DHT derivative - the most commonly reported side effect)
Acne and increased skin oiliness, particularly on the back and shoulders
Suppression of natural testosterone production (requires PCT or ongoing TRT)
Injection site pain or discomfort (more common with propionate ester)
Mild aggression or irritability from elevated androgenic activity
HDL cholesterol suppression and adverse lipid profile changes
Nandrolone
Suppression of natural testosterone production (profoundly suppressive, more so than testosterone alone)
Water retention and bloating (less than testosterone at equianabolic doses)
Erectile dysfunction and reduced libido without concurrent testosterone ('deca dick')
Increased appetite and weight gain
Mild acne and oily skin (less pronounced than testosterone)
Elevated hematocrit and hemoglobin (erythrocytosis)
Injection site pain or discomfort
Mild mood changes (some users report increased emotional sensitivity)
Contraindications
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males
Pregnancy or potential for pregnancy (causes virilization of female fetus)
Known hypersensitivity to drostanolone or any formulation components
Severe hepatic impairment
Pre-existing significant hair loss where further androgenic exposure is unacceptable
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled cardiovascular disease or severe dyslipidemia
Prostate cancer (active or history of hormone-sensitive prostate cancer)
Breast cancer in males or females
Pregnancy or potential for pregnancy (Category X - causes virilization of female fetus)
Nephrosis or the nephrotic phase of nephritis
Severe hepatic impairment
Hypercalcemia
Known hypersensitivity to nandrolone or any formulation components
Polycythemia (hematocrit above 54% at baseline)
Uncontrolled heart failure or severe cardiovascular disease
Research Evidence
Masteron Nandrolone
Status Moderate Research FDA Approved
References 5 studies 5 studies
Latest March 2020 April 2005
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.